PMCPA Case Analysis

Over 2,000 real rulings β€” analysed for what they mean to your team. Published every day.

All Cases PMCPA Case of the Week PMCPA Cases

Showing 1914 cases

2019
CASE
AUTH/3194/4/19 GlaxoSmithKline ⭐ Case of the Week

AUTH/3194/4/19: Anonymous v GlaxoSmithKline (sponsored COPD therapy review service) – No breach

Complaint alleged a third-party email linked GSK-sponsored COPD therapy reviews to β€œclient product/therapy priorities”. Panel and Appeal Board had concerns about the…

2019
CASE
AUTH/3292/12/19

AUTH/3292/12/19: Employee complaint about ECR β€˜round table’ dinner and compliance culture at GE Healthcare (No breach)

Employee alleged an ECR Vienna β€˜round table’ was really a dinner to gain favour and raised concerns about β€˜grey areas’ culture and…

2019
CASE
UCB

UCB: Out-of-date Neupro prescribing information found on internal test webpage (no breach)

Complaint alleged Neupro online prescribing info was out of date and omitted rhabdomyolysis. Panel found the page was an internal test URL…

2020
CASE
AUTH/3364/6/20 AstraZeneca

AstraZeneca LinkedIn post about COVID-19 antibodies and a β€˜potential’ vaccine: no breach on appeal (AUTH/3364/6/20)

Complaint alleged a senior exec’s LinkedIn post (and UK staff β€˜likes’) promoted an unlicensed COVID-19 vaccine to the public. Appeal Board found…

2019
CASE
A Menarini

A.Menarini: UK employee’s accidental LinkedIn β€˜like’ brought global pipeline press release into scope (breach of Clause 9.1)

A UK employee accidentally β€˜liked’ a global Menarini LinkedIn post about positive early data for an investigational AML compound. Panel said this…

2020
CASE
AUTH/3400/10/20 Novartis Pharmaceuticals UK ⭐ Case of the Week

Novartis breached Code over third‑party video series seen as pre‑licence promotion of inclisiran (AUTH/3400/10/20)

Novartis-funded third‑party β€œmedical education” videos were ruled promotional for unlicensed inclisiran, lacked clear sponsorship disclosure and certification, and breached multiple Code clauses…

2020
CASE
AUTH/3442/12/20 GlaxoSmithKline

GSK LinkedIn posts about Phase 3 RSV vaccine candidate and Covid-19 antibody trial: no breach (AUTH/3442/12/20)

Complaint alleged GSK promoted unlicensed products to the public via LinkedIn posts about Phase 3 RSV and Covid-19 antibody trials. Panel ruled…

2021
CASE
AUTH/3466/2/21 Lundbeck

Lundbeck corporate website: partial takedown altered a certified site (AUTH/3466/2/21)

Complaint about Lundbeck’s UK corporate website linking to global pages and alleged lack of reapproval. Panel found no promotion/public access breach, but…

2020
CASE
AUTH/3397/10/20 Leo

AUTH/3397/10/20: Anonymous complainant v Leo (PharmaBoardroom executive interviews) β€” No breach

Complaint about Leo executives’ online interviews on pharmaboardroom.com (UK-registered publisher). Panel/Appeal Board found the material was not promotional to UK audiences; no…

2020
CASE
AUTH/3430/11/20 AstraZeneca

AstraZeneca: LinkedIn post and employee β€˜likes’ held to promote unlicensed Covid-19 vaccine (AUTH/3430/11/20)

A senior AstraZeneca employee’s LinkedIn post linking to a vaccine efficacy press release, amplified by UK staff β€˜likes’, was ruled promotion of…

2019
CASE
Tillotts Pharma UK ⭐ Case of the Week

Tillotts: β€œCorporate announcement” in BMJ ruled promotional for Dificlirβ€”missing prescribing info and AE reporting

BMJ ad framed as an acquisition announcement for Dificlir was ruled promotional. It lacked prescribing information and an adverse event reporting statement,…

2021
CASE
AUTH/3544/7/21 Lundbeck

AUTH/3544/7/21: Anonymous v Lundbeck β€” representative contact and call rates (No breach)

Anonymous complaint alleged excessive rep calls, lack of SOP guidance and uncertified virtual materials (Jul 2020–Jun 2021). Panel found complainant didn’t meet…

2021
CASE
AUTH/3567/10/21 Zogenix

Employee v Zogenix (AUTH/3567/10/21): Advisory board concerns in Eastern Europe – no breach

Anonymous employee alleged improper planning/certification of advisory boards in Croatia, Poland and Hungary and conflicts of interest. Panel found allegations unproven; no…

2021
CASE
AUTH/3524/6/21 GlaxoSmithKline

GSK LinkedIn post about COVID-19 vaccine collaboration (Medicago/Covifenz): no breach after appeal (AUTH/3524/6/21)

A UK health professional challenged a GSK global LinkedIn post about positive interim Phase 2 results in a COVID-19 vaccine collaboration. Panel…

2022
CASE
AUTH/3608/2/22 AstraZeneca

AUTH/3608/2/22: Complainant v AstraZeneca β€” LinkedIn World Cancer Day post alleged public promotion (No breach)

A medical oncologist alleged an AstraZeneca senior employee’s LinkedIn post promoted oncology portfolio/pipeline to the public. Panel found no direct product/pipeline promotion…

Ask questions about any PMCPA case

Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases β€” ask about precedents, clauses, and how they apply to your situation.

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training